Oncology
Lung Cancer May Be Entering the Chemo-Replacement Fight
Phase III data reported in The Lancet and highlighted this week show sacituzumab tirumotecan plus pembrolizumab improved progression-free survival versus pembrolizumab alone in PD-L1-positive advanced NSCLC. The ADC era is moving into first-line lung cancer, but toxicity and sequencing will decide how far it goes.
Personalised Cancer Vaccines Show Longer-Term Staying Power
Oral SERDs Face the Hard Test: Where Do They Actually Fit?
Prostate Cancer Value Starts Counting Cognition
China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone
The ASCO Drug Race Still Runs Through Genomic Testing
High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts
Physical activity continues to strengthen its case as a cross-disease prevention strategy
An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer
Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.